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Lowblood pressure and adverse outcomes in acute
stroke: HeadPoSTstudy explanations
Menglu Ouyanga,b, Paula Mun˜oz-Venturellia,c,d, Laurent Billota, Xia Wanga, Lili Songa,b,
Hisatomi Arimaa,e, Pablo M. Lavadosd, Maree L. Hacketta,f, Vero´nica V. Olavarrı´ad,
Alejandro Brunserd, Sandy Middletong, Octavio M. Pontes-Netoh, Tsong-Hai Leei,
Caroline L. Watkinsf, Thompson Robinsonj, and Craig S. Andersona,b,c,k,l
Objective: As uncertainties exist over underlying causes,
we aimed to define the characteristics and prognostic
significance of low blood pressure (BP) early after the
onset of acute stroke.
Methods: Post hoc analyzes of the international Head
Positioning in acute Stroke Trial (HeadPoST), a pragmatic
cluster-crossover randomized trial of lying flat versus sitting
up in stroke patients from nine countries during 2015–
2016. Associations of baseline BP and death or
dependency [modified Rankin scale (mRS) scores 3–6] and
serious adverse events (SAEs) at 90 days were assessed in
generalized linear mixed models with adjustment for
multiple confounders. SBP and DBP was analysed as
continuous measures fitted with a cubic spline, and as
categorical measures with low (<10th percentile) and high
(140 and 90 mmHg, respectively) levels compared with
a normal range (10th percentile; 120–139 and 70–
89 mmHg, respectively).
Results: Among 11 083 patients (mean age 68 years,
39.9% women) with baseline BP values, 7.2 and 11.7%
had low SBP (<120 mmHg) and DBP (<70 mmHg),
respectively. Patients with low SBP were more likely to
have preexisting cardiac and ischemic stroke and functional
impairment, and to present earlier with more severe
neurological impairment than other patients. Nonlinear ‘J-
shaped’ relationships of BP and poor outcome were
apparent: compared with normal SBP, those with low SBP
had worse functional outcome (adjusted odds ratio 1.27,
95% confidence interval 1.02–1.58) and more SAEs,
particularly cardiac events, with adjustment for potential
confounders to minimize reverse causation. The findings
were consistent for DBP and were stronger for ischemic
rather than hemorrhagic stroke.
Conclusion: The prognostic significance of low BP on
poor outcomes in acute stroke was not explained by
reverse causality from preexisting cardiovascular disease,
and propensity towards greater neurological deficits and
cardiac events. These findings provide support for the
hypothesis that low BP exacerbates cardiac and cerebral
ischemia in acute ischemic stroke.
Keywords: acute stroke, blood pressure, hypotension,
outcome, trial
Abbreviations: AIS, acute ischemic stroke; BP, blood
pressure; CI, confidence interval; GLM, generalized linear
mixed model; HeadPoST, Head Positioning in acute Stroke
Trial; ICH, intracerebral hemorrhage; mRS, modified Rankin
scale; NIHSS, National Institutes of Health Stroke Scale; OR,
odds ratio; SAE, serious adverse events
INTRODUCTION
B
lood pressure (BP) is often altered in acute stroke
[1–3], typically as an acute hypertensive (physio-
logical) response (SBP 140 mmHg and/or DBP
90mmHg within 24 h of symptom onset), presumably
related to cerebral ischemia and/or elevated intracranial
pressure. Observational studies are consistent in showing
that high BP is positively associated with adverse clinical
outcomes [4,5]. However, randomized controlled trials of
blood pressure lowering have produced mixed results [6,7],
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although any benefits on functional recovery appear more
likely for intracerebral hemorrhage (ICH) [7] than acute
ischemic stroke (AIS) [8]. Although the prognostic signifi-
cance of the less frequent situation of low presentation BP
(variously defined by SBP <120, <130, or <155 mmHg) in
an acute stroke is well recognized [9–14], uncertainties exist
over whether this represents a risk factor or risk marker in
relation to premorbid factors in final few years of life [15] or
critical cerebral injury from impaired perfusion pressure in
acute stroke. Herein, we report post hoc secondary anal-
yses of the Head Positioning in acute Stroke Trial (Head-
PoST) dataset, where the systematic assessment of a large
and broad range of relatively unselected patients provided
us with an opportunity to determine relationships of low
baseline BP and the patterns of functional recovery and
serious adverse events (SAEs), overall and by major patho-
logical subtype of acute stroke.
METHODS
Study design
HeadPoST was an international, pragmatic, multicenter,
cluster crossover, clinical trial involving 11 093 adults
(18 years) with acute stroke who were randomly allocated
to the lying flat or sitting up head position at a median time
of 14 h (interquartile range 5–35 h) after symptom onset at
114 hospitals in nine countries between March 2015 and
November 2016 [16].
Standard protocol approvals, registrations, and
patient consents
Relevant hospital ethics committees or institutional review
boards approved the study, which included the use of a
cluster guardian consent to allow implementation of the
randomized intervention as a policy of usual service deliv-
ery for a predefined patient cluster; patients only provided
written consent for use of their medical record data and
release of personal information to allow centralized tele-
phone interview for follow-up at 90 days. The study is
registered at ClinicalTrials.gov (NCT02162017).
Procedures
Demographic information, clinical data, including the
severity of neurological impairment according to the
National Institutes of Health Stroke Scale (NIHSS). The
NIHSS is a measure of neurological impairment caused
by a stroke, composed of 11 items, each of which scores
a specific ability between a 0 and 4. For each item, a score of
0 typically indicates normal function in that specific ability,
while a higher score is indicative of some level of
impairment. The individual scores from each item are
summed in order to calculate a patient’s total NIHSS score,
ranging from 0 to 42. Baseline BP were collected at the time
of presentation/admission to hospital. Trained and certified
staff, blind to treatment allocation, contacted patients not
known to have died by telephone to assess their functional
status on the modified Rankin scale (mRS) at 90 days. The
mRS is a global, seven-level assessment of disability, in
which scores of 0 or 1 indicate good function without or
with symptoms but no disability, scores of 2 indicates slight
disability, 3 to 5 indicate increasing levels of disability (and
dependency), and a score of 6 indicates death. The primary
outcome for these analyses was death or dependency (mRS
scores 3–6), and secondary outcomes were all-cause and
cause-specific SAEs, as reported by site investigators and
coded centrally according to standard definitions.
Statistical analysis
Descriptive statistics were reported across categories with
ANOVA for normally distributed data, Kruskal–Wallis test
for skewed continuous variables, and chi-squared test for
categorical variables. Generalized linear mixed (GLM)
models were built with initial adjustment for the study
design of the fixed effects of head position (lying-flat versus
sitting-up) and cross-over period, random effects of cluster,
and random interaction effects between cluster and cross-
over period; and then adjusted for clinical risk factors with P
less than 0.1 (listed in Table 1 and Supplemental Table e-1,
http://links.lww.com/HJH/B455) to determine the esti-
mates of low SBP and DBP on outcomes, respectively.
Restricted cubic splines was used to visualize the relation-
ships of baseline SBP and DBP as continuous variables and
outcomes in the models, fitted with three to five knots with
placement recommended by Harrell [17] and optimal knots
selected according to the likelihood ratio test and Aikaike
information classification (AIC). The point of lowest odds
ratio (OR) was used as the optimal reference. To explore
associations of categorical BP and clinical outcomes, the
first decile of BP (121 mmHg for SBP and 68mmHg for
DBP) were used to define the ranges of low BP in the study
population (<120 mmHg in SBP and <70mmHg in DBP
being considered for meaningful interpretability). High BP
was defined as at least 140 and at least 90mmHg in SBP and
DBP, respectively, according to guidelines [18]. The primary
analysis were according to the intention-to-treat popula-
tion, with stratified analyses conducted by final diagnoses
of AIS or ICH. Prespecified subgroup analyses were per-
formed by ethnicity (Asian vs. non-Asian), use of intensive
BP-lowering treatment, preuse of antihypertensive agents,
and randomized head position. In view of the high propor-
tion (12%) of missing 90-day mRS data, multiple imputation
was conducted as a sensitivity analysis with all missing
covariates and outcome variable imputed [19] in a mixed
model for analysis of the main results (see Supplemental
Appendix, http://links.lww.com/HJH/B455). Data are
reported with OR and 95% confidence intervals (CI), with
a two-sided P less than 0.05 considered statistically signifi-
cant. All analyses were performed with SAS version 9.3 (SAS
Institute, Cary, North Carolina, USA) and STATA version 15
(StataCorp, College Station, Texas, USA).
Data availability
Individual de-identified participant data used in these anal-
yses may be shared by request from any qualified investi-
gator via the Research Office of The George Institute for
Global Health, Australia.
RESULTS
A total of 11 083 patients (mean age 68 years, 39.9% women)
had baseline BP recorded, of whom 64.7% had a history of
hypertension and 85.6% had a final diagnosis of AIS (Table 1
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and Table e-1, http://links.lww.com/HJH/B455). Overall,
their mean baseline SBP and DBP were 155 and 87mmHg,
respectively, and 7.2% were defined as having low SBP
(<120mmHg). Compared with other patients, those with
low SBP were younger, less likely to have history of hyper-
tension, and more likely to have comorbid heart disease and
functional impairment, and greater neurological impairment
and strokes without brain imaging confirmation (Table 1). In
multivariable analysis, history of atrial fibrillation, coronary
disease, heart failure and current smoking were related to
increased risk of low BP at presentation (Table e-2, http://
links.lww.com/HJH/B455).
Low SBP and clinical outcomes
After adjustment for study design and various potential
confounding baseline factors, restricted cubic splines
regression curves show a nonlinear ‘J-shaped’ relationship
between baseline SBP and death or dependency, with the
odds increasing for SBP levels less than 130 mmHg (Fig. 1a)
and in those with a final diagnosis of AIS rather than ICH
(Fig. 2). Patients with low SBP had an increased risk of
death or dependency in the main analysis (adjusted OR
1.27, 95% CI 1.02–1.58; Fig. 3), which was consistent after
multiple imputation (adjusted OR 1.26, 95% CI 1.02–1.56;
Fig. 3). Risks of death and any SAE were also higher in
patients with low SBP, with the latter related to an increased
risk of cardiac events (Table 2). Similar J-shaped relation-
ships were found for SBP and SAEs, with adjusted OR
increasing with SBP less than 140 mmHg (Fig. 1b). Com-
pared with those with AIS, ICH patients were more likely to
present with high SBP (140 mmHg; Table 1), which sig-
nificantly increased the risk of SAEs compared with those
with normal SBP (adjusted OR 2.31, 95% CI 1.16–4.60;
Figure e-1A, http://links.lww.com/HJH/B455).
TABLE 1. Baseline characteristics by categories of SBP
SBP (mmHg)
Variable Overall <120 120–139 140 P value
Number of patients 11083 795 (7.2) 2393 (21.6) 7895 (71.2)
Age (years) 68 (13.8) 65 (15.5) 66 (14.6) 69 (13.2) <0.0001
Female 4423 (39.9) 300 (37.7) 888 (37.1) 3235 (41.0) 0.0012
Region <0.0001
Australia and UK 4754 (42.9) 390 (49.1) 971 (40.6) 3393 (43.0)
China and Taiwan 4652 (42.0) 245 (30.8) 1056 (44.1) 3351 (42.4)
South America 910 (8.2) 83 (10.4) 179 (7.5) 645 (8.2)
India and Sri Lanka 770 (6.9) 77 (9.7) 187 (7.8) 506 (6.4)
Clinical features
Final pathological type of stroke <0.0001
AIS 9467 (85.6) 675 (85.1) 2086 (87.4) 6701 (85.1)
ICH 930 (8.4) 39 (4.9) 123 (5.1) 768 (9.8)
Uncertain 696 (6.0) 79 (10.0) 178 (7.5) 405 (5.1)
Severity of neurological impairment, NIHSS scorea 4 (2–8) 5 (2–10) 4 (2–8) 4 (2–8) 0.0002
Score 15 1207 (11.1) 112 (14.3) 240 (10.2) 855 (11.0) 0.0079
SBP (mmHg) 151 (136–171) 110 (105–116) 130 (125–134) 162 (150–180) <0.0001
DBP (mmHg) 85 (76–97) 70 (61–75) 80 (70–84) 90 (80–100) <0.0001
Time from onset (h) 7.5 (2.3–26.8) 6.4 (2.0–25.3) 8.9 (2.5–31.8) 7.2 (2.3–25.9) <0.0001
Medical history
Hypertension 7148 (64.7) 382 (48.2) 1310 (54.8) 5456 (69.3) <0.0001
Current treatment 5616 (50.7) 322 (40.6) 1055 (44.1) 4238 (53.7) 0.0007
Number of antihypertensive agents 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) 0.0030
Diabetes mellitus 2650 (24.0) 159 (20.1) 546 (22.9) 1945 (24.7) 0.0054
Atrial fibrillation 1189 (10.8) 112 (14.1) 287 (12.0) 790 (10.1) 0.0002
Coronary disease 1540 (14.0) 141 (17.8) 361 (15.1) 1038 (13.2) 0.0003
Heart failure 413 (3.8) 53 (6.7) 105 (4.4) 255 (3.3) <0.0001
Previous stroke 2605 (23.6) 189 (23.9) 571 (23.9) 1845 (23.4) 0.8779
Smoking 2124 (19.4) 177 (22.7) 519 (21.9) 1428 (18.3) <0.0001
High level of premorbid function (mRS 0–1)b 8733 (78.9) 603 (75.9) 1860 (77.8) 6270 (79.5) 0.0205
Hypercholesterolemia 2731 (24.6) 215 (27.3) 591 (24.8) 1925 (24.5) 0.2175
COPD/emphysema 406 (3.7) 37 (4.7) 78 (3.3) 291 (3.7) 0.1809
Medications
Aspirin/other antiplatelet 5398 (48.7) 387 (48.7) 1249 (52.2) 3762 (47.7) 0.0005
Anticoagulation 951 (8.6) 87 (11.0) 223 (9.3) 641 (8.1) 0.0088
Statin/other lipid lowering 2295 (20.7) 188 (23.6) 501 (20.9) 1606 (20.3) 0.2219
Data are mean (SD), median (IQR), and n (%). Analyses were ANOVA test for normally distributed variables, Kruskal–Wallis test for skewed continuous variables, and chi-squared test for
categorical variables. AIS, acute ischemic stroke; COPD, chronic obstructive pulmonary disease; ICH, intracerebral hemorrhage; mRS, modified Rankin scale; NIHSS, National Institutes of
Health Stroke Scale; UK, United Kingdom.
aNIHSS is a measure of neurological impairment caused by a stroke, composed of 11 items, each of which scores a specific ability from 0 up to 4. For each item, a score of 0 typically
indicates normal function in that specific ability, whereas a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate
a patient’s total NIHSS score, ranging from 0 to 42.
bThe mRS represents a global, seven-level assessment of disability, in which score of 0 or 1 indicate good function without or with symptoms but no disability, score of 2 indicates slight
disability, scores of 3–5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.
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Low DBP and clinical outcomes
A similar relationship applied for DBP, with odds of poor
outcome increasing with DBP levels less than 90mmHg,
overall and in those with AIS and ICH (Figures e-2A, http://
links.lww.com/HJH/B455 and e-3, http://links.lww.com/
HJH/B455). Similar associations were identified for low
DBP and poor outcome, where patients with low DBP
had an increased risk of death or dependency in the main
analysis (adjusted OR 1.25, 95% CI 1.06–1.48), which was
consistent after multiple imputation (adjusted OR 1.20, 95%
CI 1.03–1.40) (Figure e-4, http://links.lww.com/HJH/
B455). There was a nonlinear relationship between DBP
and SAE (Figure e-2B, http://links.lww.com/HJH/B455),
but this association was not significant when compared
with a normal range (70–89mmHg) of DBP (Figure e-1B,
http://links.lww.com/HJH/B455).
Subgroup analysis
Heterogeneity was found in the association between low
BP and outcome, comparing Asian (n¼ 4947) and non-
Asian (n¼ 4428) patients, with the former having a signifi-
cantly higher risk of poor outcome at 90 days (SBP, adjusted
OR 1.53, 95% CI 1.11–2.11, Figure e-5, http://link-
s.lww.com/HJH/B455; DBP, adjusted OR 1.38, 95% CI
1.05–1.81, Figure e-6, http://links.lww.com/HJH/B455).
However, for non-Asian patients, high BP was associated
with lower risk of poor outcome (SBP, adjusted OR 0.78,
95% CI 0.65–0.94, Figure e-5, http://links.lww.com/HJH/
B455; DBP, adjusted OR 0.80, 95% CI 0.68–0.94, Figure e-6,
http://links.lww.com/HJH/B455). No heterogeneity was
found in subgroup analysis by use of intensive BP lowering
during hospitalization, prior use of antihypertensive treat-
ment, or randomized head positioning, and death or
FIGURE 2 Restricted cubic spline of baseline SBP and 90-day death or depen-
dency, by stroke subtype. Generalized linear mixed model fitted were used with
adjustment for study design (fixed effects of head position and cross-over period,
random effects of cluster, and random interaction effects between cluster and
crossover period) and potential baseline confounders of age, sex, region, history of
diabetes mellitus, hypertension, heart failure, atrial fibrillation, coronary heart dis-
ease, National Institutes of Health Stroke Scale score, pathological stroke type,
premorbid score 0–1 on the modified Rankin scale, aspirin/other antiplatelet treat-
ment, anticoagulant treatment, time from stroke onset to hospital arrival and
current smoking. Splines fitted with five knots (percentiles 5th, 27.5th, 50th,
72.5th, 95th) for SBP. Reference SBP 140 mmHg. Solid line indicates odds ratios;
dotted line indicates 95% confidence intervals. AIS, acute ischemic stroke; ICH,
intracerebral hemorrhage.
FIGURE 1 Restricted cubic spline of baseline SBP and clinical outcomes at 90 days.
Generalized linear mixed models were used with adjustment for study design
(fixed effects of head position and cross-over period, random effects of cluster,
and random interaction effects between cluster and crossover period) and poten-
tial baseline confounders of age, sex, region, history of diabetes mellitus, hyper-
tension, heart failure, atrial fibrillation, coronary heart disease, National Institutes
of Health Stroke Scale score, pathological stroke type, premorbid score 0–1 on
the modified Rankin scale, aspirin/other antiplatelet treatment, anticoagulant treat-
ment, time from stroke onset to hospital arrival and current smoking. (a) Spline
fitted with five knots (percentiles 5th, 27.5th, 50th, 72.5th, 95th) for SBP; (b)
Spline fitted with four knots (percentiles 5th, 35th, 65th, 95th) for SBP. Reference
SBP 140 mmHg. Solid line indicates odds ratios; dotted line indicates 95% confi-
dence intervals. SAE, serious adverse events.
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dependency (Figures e-5, http://links.lww.com/HJH/B455
and e-6, http://links.lww.com/HJH/B455).
DISCUSSION
In these secondary analyzes of a large and heterogenous
international clinical cohort, low BP early after hospital
presentation for acute stroke was associated with increased
odds of poor clinical outcome after full adjustment for many
potential confounding factors. The findings of consistency
in the association for both SBP and DBP on functional
recovery and cardiac SAEs, and being greater for AIS than
ICH, provides support for the common concern for an
interaction between low BP and cardiac and cerebral hypo-
perfusion and ischemia [1].
Most guidelines provide recommendations on the man-
agement of BP in AIS [20] and particularly ICH [20,21],
principally as hypertension is a commonly observed phe-
nomenon [22–24] with a well documented relation to
increased adverse outcomes [25]. Although less frequently
observed, low BP is also clearly not a benign phenomenon.
Previous observational studies have found J-curve relation-
ships between BP and adverse outcomes in relation to
various heart diseases [26–28], and proposing ‘reverse
causation’ as the basis for the progression of heart failure
with premorbid comorbidities and frailty [29]. Similarly for
stroke, one study has shown that low SBP (<120 mmHg)
after recent AIS is related to increased recurrent stroke and
vascular death [30], whereas another showed that diastolic
hypotension increased the risks of death, myocardial
FIGURE 3 Association of categorical baseline SBP and 90-day death or dependency, by dataset. Generalized linear mixed model fitted were used with adjustment for study
design (fixed effects of head position and cross-over period, random effects of cluster, and random interaction effects between cluster and crossover period) and potential
baseline confounders of age, sex, region, history of diabetes mellitus, hypertension, heart failure, atrial fibrillation, coronary heart disease, National Institutes of Health
Stroke Scale score, pathological stroke type, premorbid score 0–1 on the modified Rankin scale, aspirin/other antiplatelet treatment, anticoagulant treatment, time from
stroke onset to hospital arrival and current smoking. Reference SBP 120–139 mmHg. Boxes indicate point estimate of odds ratios, solid line indicates 95% confidence
intervals. AIS, acute ischemic stroke; aOR, adjusted odds ratio; CI, confidence interval; ICH, intracerebral hemorrhage; OR, odds ratio.
TABLE 2. Outcomes at 90 days by baseline SBP
SBP (mmHg)
Outcome <120 120–139 140 P value
Death or dependency (mRSa 3–6) 296/669b (44.2) 778/2084b (37.3) 2746/6986b (39.3) 0.0060
Disability (mRSa 3–5) 228/669 (34.1) 607/2084 (29.1) 2189/6986b(31.3) 0.0349
Death 68/669 (8.7) 171/2084 (7.3) 557/6986 (7.2) 0.3308
SAE 138/795c (17.4) 303/2393c (12.7) 1098/7895c (13.9) 0.0040
Recurrent stroke 43/795 (5.4) 104/2393 (4.4) 380/7895 (4.8) 0.4289
Cardiac or other vascular events 26/795 (3.3) 40/2393 (1.7) 169/7895 (2.1) 0.0247
Pneumonia 23/795 (2.9) 54/2393 (2.3) 215/7895 (2.7) 0.4103
Other infection 11/795 (1.8) 28/2393 (1.2) 79/7895 (1.0) 0.1326
Other SAE 28/795 (3.5) 60/2393 (2.5) 197/7895 (2.5) 0.2134
Data are n/N (%); P value from chi-squared test. mRS, modified Rankin scale; SAE, serious adverse event.
aThe mRS represents a global, seven-level assessment of disability, in which scores of 0 or 1 indicate good function without or with symptoms but no disability, score of 2 indicates
slight disability, scores of 3–5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.
bN is according to total number of patients at 90-day follow-up.
cN is according to total number of patients randomized.
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infarction [31], and recurrent vascular events including
stroke [32]. There is a strong argument that a reduction
in systematic BP may worsen cerebral ischemia in relation
to altered cerebral autoregulation in the vulnerable pen-
umbral region of AIS [33], whereas comorbidity and greater
neurological severity in those presenting with hypotension,
may partly explain the increase in SAEs shown in previous
acute stroke trials [34]. Although low BP in frail older
patients might be a harbinger of preterminal decline [35],
we found the increased risk of adverse events in stroke
patients with low BP persisted after adjustment for pre-
morbid disability and comorbid heart disease.
Our study also found that the prognostic significance of
low BP was modified by ethnicity, with Asian patients
having a worse outcome irrespective of BP than non-
Asians, who had a comparably lower odds of death or
dependency from low BP. Although some studies have also
shown poorer functional outcome in Asian compared with
European stroke patients [36], there are limited data spe-
cifically pertaining to ethnicity and low BP. Yet, ethnic
disparities in cardiovascular risk factor control, as well as
acute stroke care, and regional differences in rehabilitation,
might explain some of this variation [37].
In addition to the large sample size and systematic
recording of outcomes, key strengths of our study were
the steps taken to adjust for many potential confounding
factors and to minimize potential reverse causation. More-
over, the generalizability of the results is enhanced by the
use of broad inclusion criteria applied to AIS and ICH
patients recruited in multiple countries. However, as the
HeadPoST study was a pragmatic clinical trial focused on
different head positions after stroke, there were limited in-
hospital BP measures recorded for the study or these were
measured BP according to local protocols, although any
effect of BP misclassification would be to attenuate the
strength of associations. In addition, we did not have data
concerning dose of prior antihypertensive therapy nor use
of other cardiac medications, although the frequency of
hypertension and number of antihypertensive agents were
greater in those patients presenting with elevated BP. Other
limitations related to these being secondary analyses with
relatively small number of patients in subgroups, variable
cut-points to define BP categories, and missing or misclas-
sification of confounding covariates.
In conclusion, our study has shown that low presenting
BP, both SBP and DBP, are associated with poor outcome
after acute stroke, even after taking account of these
patients being a particularly high-risk group from having
preexisting cardiac or cerebral cardiovascular comorbidity
and dependency/frailty; and of the severity of neurological
injury. As well as alerting clinicians to the care of these
vulnerable patients, there may be merit in further studies
being undertaken to better define the mechanisms of low
BP on the cerebral circulation, and the most appropriate
management strategies for low BP.
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